Ballal Rahul D.'s Form 4 filing
Agios Pharmaceuticals, Inc. (AGIO) · filed Nov 12, 2024
- Accession no.
- 0001439222-24-000142
- Filed
- Nov 12, 2024
- Trade date
- Nov 7-8, 2024
- Filing delay
- 5 days
- Rule 10b5-1 plan
- Checked
This filing lists 7 non-derivative transactions and 2 derivative transactions. Open-market sales total $1.12M. It was filed 5 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Ballal Rahul D.CIK 0001805097 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 7, 2024 | Common stock | MOption exerciseAcquired | +10,000 | $25.99 | +$259,900 | 17,992 | Direct | |
| Nov 7, 2024 | Common stock | SSaleDisposed | −8,132 | $53.32F2 | −$433,598.24 | 9,860 | Direct | |
| Nov 7, 2024 | Common stock | SSaleDisposed | −1,868 | $54.41F3 | −$101,637.88 | 7,992 | Direct | |
| Nov 8, 2024 | Common stock | MOption exerciseAcquired | +10,000 | $25.99 | +$259,900 | 17,992 | Direct | |
| Nov 8, 2024 | Common stock | SSaleDisposed | −3,571 | $57.24F4 | −$204,404.04 | 14,421 | Direct | |
| Nov 8, 2024 | Common stock | SSaleDisposed | −4,929 | $58.57F5 | −$288,691.53 | 9,492 | Direct | |
| Nov 8, 2024 | Common stock | SSaleDisposed | −1,500 | $59.21F6 | −$88,815 | 7,992 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 7, 2024 | Common stock | MOption exerciseDisposed | −10,000 | $0.00 | $0 | 27,947 | Direct | |
| Nov 8, 2024 | Common stock | MOption exerciseDisposed | −10,000 | $0.00 | $0 | 17,947 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $53.00 to $53.84. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.
- F3
The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $54.02 to $54.60. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.
- F4
The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $57.00 to $58.00. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.
- F5
The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $58.00 to $58.99. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.
- F6
The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $59.01 to $59.37. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.